Figure 5.
(A) Kaplan Meier analysis of recurrence free survival (RFS) in four subgroups according to the IL12B expression levels and gender. (B) Comparisons of IL12B expression between tumor samples of lung adenocarcinoma (LUAD) patients with different genders. (C) Kaplan Meier analysis of RFS in eight LUAD patient subgroups according to IL12B expression levels and tumor stage. (D) Comparisons of IL12B expression between tumor samples of LUAD patients at different pathological stages. (E) Kaplan Meier analysis of RFS in four LUAD patient subgroups according to the IL12B expression levels and EGFR mutation status. (F) Kaplan Meier analysis of RFS in four LUAD patient subgroups according to the IL12B expression levels and KRAS mutation status.